Stock Scorecard
Stock Summary for HUTCHMED (China) Ltd (HCM) - $17.45 as of 9/19/2025 2:45:58 PM EST
Total Score
14 out of 30
Safety Score
36 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for HCM
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for HCM
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for HCM
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for HCM
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for HCM (36 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 1 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for HCM
Financial Details for HCM
Company Overview |
|
|---|---|
| Ticker | HCM |
| Company Name | HUTCHMED (China) Ltd |
| Country | USA |
| Description | HUTCHMED (China) Limited is a leading biopharmaceutical company focused on discovering, developing, and marketing innovative targeted therapies and immunotherapies for cancer and immune-related diseases in global markets. Headquartered in Central, Hong Kong, HUTCHMED leverages cutting-edge research and extensive clinical development capabilities to address unmet medical needs in oncology. With a robust pipeline and strategic partnerships, the company is well-positioned to capitalize on the growing demand for advanced cancer treatments, enhancing its potential for sustainable growth and value creation for shareholders. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 11/14/2025 |
Stock Price History |
|
| Last Day Price | 17.45 |
| Price 4 Years Ago | 35.08 |
| Last Day Price Updated | 9/19/2025 2:45:58 PM EST |
| Last Day Volume | 28,225 |
| Average Daily Volume | 58,987 |
| 52-Week High | 21.50 |
| 52-Week Low | 11.51 |
| Last Price to 52 Week Low | 51.61% |
Valuation Measures |
|
| Trailing PE | 6.58 |
| Industry PE | 91.84 |
| Sector PE | 40.55 |
| 5-Year Average PE | 40.84 |
| Free Cash Flow Ratio | 19.39 |
| Industry Free Cash Flow Ratio | 14.88 |
| Sector Free Cash Flow Ratio | 29.46 |
| Current Ratio Most Recent Quarter | 4.65 |
| Total Cash Per Share | 0.90 |
| Book Value Per Share Most Recent Quarter | 1.43 |
| Price to Book Ratio | 2.44 |
| Industry Price to Book Ratio | 12.17 |
| Sector Price to Book Ratio | 32.17 |
| Price to Sales Ratio Twelve Trailing Months | 4.98 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.86 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.16 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 171,860,000 |
| Market Capitalization | 2,998,957,000 |
| Institutional Ownership | 3.63% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 1,633.00% |
| Annual Earnings Growth | -62.56% |
| Reported EPS 12 Trailing Months | 2.65 |
| Reported EPS Past Year | 0.52 |
| Reported EPS Prior Year | 0.01 |
| Net Income Twelve Trailing Months | 37,729,000 |
| Net Income Past Year | 37,729,000 |
| Net Income Prior Year | 100,780,000 |
| Quarterly Revenue Growth YOY | -9.20% |
| 5-Year Revenue Growth | 25.20% |
| Operating Margin Twelve Trailing Months | -1.27% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 153,958,000 |
| Total Cash Past Year | 153,958,000 |
| Total Cash Prior Year | 283,589,000 |
| Net Cash Position Most Recent Quarter | 60,514,000 |
| Net Cash Position Past Year | 94,524,000 |
| Long Term Debt Past Year | 59,434,000 |
| Long Term Debt Prior Year | 48,189,000 |
| Total Debt Most Recent Quarter | 93,444,000 |
| Equity to Debt Ratio Past Year | 0.93 |
| Equity to Debt Ratio Most Recent Quarter | 0.93 |
| Total Stockholder Equity Past Year | 759,929,000 |
| Total Stockholder Equity Prior Year | 730,541,000 |
| Total Stockholder Equity Most Recent Quarter | 1,229,064,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -17,436,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.10 |
| Free Cash Flow Past Year | -17,436,000 |
| Free Cash Flow Prior Year | 186,646,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.32 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | 13.00 |
| 20-Day Bollinger Middle Band | 15.77 |
| 20-Day Bollinger Upper Band | 18.53 |
| Beta | 0.47 |
| RSI | 60.56 |
| 50-Day SMA | 15.81 |
| 150-Day SMA | 15.95 |
| 200-Day SMA | 16.52 |
System |
|
| Modified | 9/18/2025 1:25:15 AM EST |